Viromed Medical AG (FRA:VME) Cyclically Adjusted FCF per Share: €0.00 (As of Dec. 2025)


FRA:VME Viromed Medical AG FRA:VME
22 GF Score
Price €6.80
! 5 Warning Signs
View Full Analysis

What is Viromed Medical AG Cyclically Adjusted FCF per Share?

Viromed Medical AG FRA:VME +0.74% 22 Cyclically Adjusted FCF per Share is €0.00 as of Dec. 2025. GuruFocus rates FRA:VME with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Viromed Medical AG's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2025 was €0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-03), Viromed Medical AG's current stock price is € 6.80. Viromed Medical AG's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2025 was €0.00. Viromed Medical AG's Cyclically Adjusted Price-to-FCF of today is .


Viromed Medical AG  (FRA:VME) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Viromed Medical AG Cyclically Adjusted FCF per Share Related Terms


Viromed Medical AG Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Viromed Medical AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG Cyclically Adjusted FCF per Share Chart

Viromed Medical AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
0.00 0.00 0.00 0.00 0.00

Viromed Medical AG Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:VME vs ABT, SYK, MDT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Viromed Medical AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viromed Medical AG Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Viromed Medical AG's Cyclically Adjusted Price-to-FCF falls into.


FRA:VME
22GF Score
Viromed Medical AG FRA:VME
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viromed Medical AG's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/129.3606*129.3606
=0.000

Current CPI (Dec. 2025) = 129.3606.

Viromed Medical AG does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.

What does a Cyclically Adjusted FCF per Share of €0.00 mean?
Viromed Medical AG (FRA:VME) has a Cyclically Adjusted FCF per Share of €0.00 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viromed Medical AG and its competitors.
Is Viromed Medical AG's Cyclically Adjusted FCF per Share too high?
Viromed Medical AG's current Cyclically Adjusted FCF per Share is €0.00. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Cyclically Adjusted FCF per Share compare to ABT and SYK?
Viromed Medical AG's Cyclically Adjusted FCF per Share of €0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viromed Medical AG and its competitors. Viromed Medical AG's current Cyclically Adjusted FCF per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (FRA:VME) has a current Cyclically Adjusted FCF per Share of €0.00. The current Cyclically Adjusted FCF per Share is €0.00. Viromed Medical AG's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Viromed Medical AG (FRA:VME), the current Cyclically Adjusted FCF per Share is €0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Other Exchanges VME:Germany
Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score

Get the complete analysis for FRA:VME

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.80
Price